Early Phase Patient Studies

Our flexible operating strategy endorses the right site – right patient model, and is tailored for small, early phase patient studies (I-IIA/Proof- of- Concept). With key partnerships and specialised expertise, we can help to mitigate risk and get insight into drug profiles, including safety signals required for decision-making. To access the right patients, we can utilise our phase I clinical research units, a selective network of trusted partner sites, or other 3rd party sites if they are better suited. This flexibility allows us to customise our strategy for every study to optimise results.

ICON Early Clinical ensures each trial receives the attention it needs, while being connected to the resources of a large, global CRO. We offer:

• Scientific services
• Flexible models
• Early phase adaptive studies
• Trusted global site network
• PK/PD modelling and simulation
• Early phase biometrics
• Integrated medical writing

We have a proven track record of helping our customers reach key milestones on time, while using cost-effective approaches.